After a test by his doctor confirmed in May that the 15-year-old Little Silver residents symptoms including excessive thirst, frequent urination and lethargy were not just those of a growing teen, but rather signs that he was diabetic, McMahon spent several days in the hospital learning how to level his glucose and inject his insulin. Jack McMahon, 15, of Little Silver, was named the American Diabetes Association’s “Face of the ADA” for the New Jersey market in August.American Diabetes Association I was afraid, Jack said in a release. The people who taught me were amazing. So patient.
For the original version including any supplementary images or video, visit http://www.nj.com/monmouth/index.ssf/2013/08/little_silver_teen_named_face_of_american_diabetes_association.html
Session on ‘Management of Diabetes in Elderly’ held in Chandigarh
The therapy, called Afrezza, is designed to treat adult patients with Type 1 and Type 2 diabetes. It consists of a powder loaded into a cartridge and used as an inhaler. Results from the two studies included reduction in fasting blood glucose levels and lower incidences of hypoglycemia. MannKind said it expects to submit data from the trials to the U.S. Food and Drug Administration in the fourth quarter ending December. (Reporting by Pallavi Ail in Bangalore; Editing by Maju Samuel)
For the original version including any supplementary images or video, visit http://www.reuters.com/article/2013/08/14/us-mannkind-study-idUSBRE97D0GG20130814
MannKind diabetes therapy succeeds in late-stage studies
Similarly, the incidence of adverse events resulting in discontinuation was low overall and balanced between the treatment groups (AFREZZA: 4.0%; oral therapy: 5.1%). The most common adverse event was cough, occurring with comparable incidence in both the AFREZZA (23.7%) group and the oral therapy (19.9%) group (who were also taking a placebo powder). Cough was predominantly dry, intermittent, and usually occurred within 10 minutes of inhalation. The incidence of cough in both treatment groups was highest during the first week of the treatment period and diminished thereafter. These preliminary results are subject to further analysis. About AFREZZA AFREZZA is a novel, ultra rapid-acting mealtime insulin therapy being developed by MannKind Corporation for the treatment of adult patients with type 1 or type 2 diabetes for the control of hyperglycemia.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/mannkind-reports-positive-data-phase-100100447.html
MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA in Patients with Type 2 Diabetes
While Type 1 diabetes accounts for 5-10% of all diabetes diagnoses, Type 2 diabetes affects almost 90-95% of the patients.” Detailing the management strategies, “Type 2 diabetes happens a lot with obese people, but obesity is not that common among older diabetes patients. In nursing homes, the problem of being underweight is as common as that of being overweight. Thus, nutritional management should focus on weight gain for underweight elderly patients as much as it is focused on weight loss for obese patients. Changes in body composition with accumulation of fat in the abdomen is a key factor in the causation of diabetes in the aging population.
For the original version including any supplementary images or video, visit http://timesofindia.indiatimes.com/city/chandigarh/Session-on-Management-of-Diabetes-in-Elderly-held-in-Chandigarh/articleshow/21803275.cms